Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?

Bibliography

• Berruti A, Generali D, Kaufmann M, et al. International expert consens us on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, cremona, italy (2010). J Natl Cancer Inst Monogr 2011;2011(43):147-51
   PubMedGoogle Scholar
• Tung N. What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer? J Clin Oncol 2013;31(11):1391-7
   Google Scholar
• Cardoso F, Loibl S, Pagani O, et al. The european society of breast cancer specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012;48(18):3355-77
   PubMed Web of Science ®Google Scholar
• Arslan UY, Turker I, Aksoy S, et al. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. J BUON 2013;18(3):585-93
   Google Scholar
• Chen X, Ye G, Zhang C, et al. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. Breast Cancer Res Treat 2013. [Epub ahead of print]
   Google Scholar
• Brunello E, Brunelli M, Manfrin E, et al. Classical lobular breast carcinoma consistently lacks topoisomerase-IIalpha gene amplification: implications for the tailored use of anthracycline-based chemotherapies. Histopathology 2012;60:482-8
   Google Scholar
• Vergine M, Brunelli M, Martignoni G, et al. Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St gallen international expert consensus meeting. Histopathology 2010;57:935-40
   Google Scholar
• Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011;378(9805):1812-23
   PubMed Web of Science ®Google Scholar
• Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216(2):141-50
   PubMed Web of Science ®Google Scholar
• Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52
   PubMed Web of Science ®Google Scholar
• Hortobagy GN, Martine J, Piccart-Gebhart MJ, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: results from BOLERO-2. 2013 ASCO annual meeting. J Clin Oncol 2013;31(Suppl):abstract LBA509
   Google Scholar
• Madden SF, Clarke C, Aherne ST, et al. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 2013;15(4):R52
   PubMed Web of Science ®Google Scholar
• Gozgit JM, Wong MJ, Moran L, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFRamplified or mutated cancer models. Mol Cancer Ther 2012;11:690-9
   PubMed Web of Science ®Google Scholar
• Patel RR, Sengupta S, Kim HR, et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer 2010;46:1537-53
   PubMed Web of Science ®Google Scholar
• Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 2009;10(7):632-44
   Google Scholar
• Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014;34(2):280-300
   PubMed Web of Science ®Google Scholar
• Grose R, Dickson C. Fibroblast growth factor signalling in tumorigenesis. Cytokine Growth Factor Rev 2005;16:179-86
   PubMed Web of Science ®Google Scholar
• Katoh M. Cancer genomics and genetics of FGFR2. Int J Oncol 2008;33:233-7
   PubMed Web of Science ®Google Scholar
• Ivan M, Matei D. Blockade of FGF signalling: therapeutic promise for ovarian cancer. Cancer Biol Ther 2010;10:505-8
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10(2):116-29
   PubMed Web of Science ®Google Scholar
• Greulich H, Pollock PM. Targetingmutant fibroblast growth factor receptors in cancer. Trends Mol Med 2011;17:283-92
   PubMed Web of Science ®Google Scholar
• Heinzle C, Sutterluty H, Grusch M, et al. Targeting fibroblast-growth-factor-receptor-dependent signalling for cancer therapy. Expert Opin Ther Targets 2011;15:829-46
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signalling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16(2):139-49
   PubMed Web of Science ®Google Scholar
• Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012;72(8):2045-56
   PubMed Web of Science ®Google Scholar
• Kono SA, Marshall ME, Ware KE, et al. The fibroblast growth factor receptor signalling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 2009;12(4-5):95-102
   PubMedGoogle Scholar
• Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics. Int J Mol Med 2009;23:307-11
   PubMed Web of Science ®Google Scholar
• Ota S, Zhou ZQ, Link JM, et al. The role of senescence and prosurvival signalling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum Mol Genet 2009;18:2609-21
   Google Scholar
• Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009;9:639-51
   PubMed Web of Science ®Google Scholar
• Nilsson EM, Brokken LJ, Harkonen PL. Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death. Exp Cell Res 2010;316:800-12
   Google Scholar
• Cuevas P, Carceller F, Angulo J, et al. Antiglioma effects of a new, low molecular mass, inhibitor of fibroblast growth factor. Neurosci Lett 2011;491:1-7
   Google Scholar
• Harmer NJ, Ilag LL, Mulloy B, et al. Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex. J Mol Biol 2004;339(4):821-34
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16(2):107-37
   PubMed Web of Science ®Google Scholar
• Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006;281(23):15694-700
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271(25):15292-7
   PubMed Web of Science ®Google Scholar
• Wu DQ, Kan MK, Sato GH, et al. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem 1991;266:16778-85
   PubMed Web of Science ®Google Scholar
• Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281(10):6120-3
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53
   PubMed Web of Science ®Google Scholar
• Tenhagen M, van Diest PJ, Ivanova IA, et al. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer 2012;19(4):R115-29
   Google Scholar
• Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011;437(2):199-213
   PubMed Web of Science ®Google Scholar
• Olsen SK, Ibrahimi OA, Raucci A, et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci USA 2004;101(4):935-40
   Google Scholar
• Acevedo VD, Ittmann M, Spencer DM. 2009 paths of FGFR-driven tumorigenesis. Cell Cycle 2009;8(4):580-8
   PubMed Web of Science ®Google Scholar
• Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24(50):7455-64
   PubMed Web of Science ®Google Scholar
• Hart KC, Robertson SC, Kanemitsu MY, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000;19:3309-20
   PubMed Web of Science ®Google Scholar
• Kang S, Elf S, Dong S, et al. Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol Cell Biol 2009;29:2105-17
   PubMed Web of Science ®Google Scholar
• Peschard P, Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 2003;3(6):519-23
   PubMed Web of Science ®Google Scholar
• Casaletto JB, McClatchey AI. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer 2012;12:387-400
   PubMed Web of Science ®Google Scholar
• Haugsten EM, Malecki J, Bjørklund SM, et al. Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis. Mol Biol Cell 2008;19(8):3390-403
   Google Scholar
• Cabrita MA, Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 2008;11:53-62
   PubMed Web of Science ®Google Scholar
• Ledda F, Paratcha G. Negative regulation of receptor tyrosine kinase (RTK) signaling: a developing field. Biomark Insights 2007;2:45-58
   Google Scholar
• Dikic I, Giordano S. Negative receptor signalling. Curr Opin Cell Biol 2003;15(2):128-35
   PubMed Web of Science ®Google Scholar
• Moelans CB, de Weger RA, Monsuur HN, et al. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 2010;23(7):1029-39
   Google Scholar
• Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009;15(2):441-51
   PubMed Web of Science ®Google Scholar
• Elbauomy Elsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007;9(2):R23
   PubMed Web of Science ®Google Scholar
• Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70(5):2085-94
   PubMed Web of Science ®Google Scholar
• Massabeau C, Sigal-Zafrani B, Belin L, et al. The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer? Breast Cancer Res Treat 2012;134(1):259-66
   Google Scholar
• Jang MH, Kim EJ, Choi Y, et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res 2012;14(4):R115
   Google Scholar
• Brunello E, Brunelli M, Bogina G, et al. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. J Exp Clin Cancer Res 2012;31:103
   PubMed Web of Science ®Google Scholar
• Brunello E, Brunelli M, Bogina G, et al. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. J Exp Clin Cancer Res 2012;31:103
   PubMed Web of Science ®Google Scholar
• Fletcher MN, Castro MA, Wang X, et al. Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun 2013;4:2464
   Google Scholar
• Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 novel breast cancer susceptibility loci. Nat Genet 2013;45(4):392-8; 398e1-2
   Google Scholar
• Couch FJ, Wang X, McGuffog L, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447(7148):1087-93
   Google Scholar
• Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39(7):870-4
   PubMed Web of Science ®Google Scholar
• Lafitte M, Moranvillier I, Garcia S, et al. FGFR3 has tumor suppressor properties in cells with epithelial phenotype. Mol Cancer 2013;12:83
   Google Scholar
• Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 2001;20(32):4416-18
   Google Scholar
• Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signalling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004;23(20):3501-8
   Google Scholar
• Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446(7132):153-8
   PubMed Web of Science ®Google Scholar
• Glénisson M, Vacher S, Callens C, et al. Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes Cancer 2012;3(1):63-70
   Google Scholar
• Kuroso K, Imai Y, Kobayashi M, et al. Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. Pathobiology 2010;77(5):231-40
   Google Scholar
• Degnin CR, Laederich MB, Horton WA. Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3. Mol Biol Cell 2011;22(20):3861-73
   Google Scholar
• Chioni AM, Grose R. FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J Cell Biol 2012;197(6):801-17
   PubMed Web of Science ®Google Scholar
• Tomlinson DC, Knowles MA, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 2012;130(12):2857-66
   Google Scholar
• Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004;111(2):213-17
   Google Scholar
• Morimoto Y, Ozaki T, Ouchida M, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003;98(10):2245-50
   Google Scholar
• Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. Cancer 2003;98(10):2245-50
   Google Scholar
• da Costa Andrade V, Parise O, Hors C, et al. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007;82(1):53-7
   Google Scholar
• Frullanti E, Berking C, Harbeck N, et al. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev 2011;20(4):340-7
   PubMed Web of Science ®Google Scholar
• Marme´ F, Hielscher T, Hug S, et al. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer 2012;131(4):E586-91
   Google Scholar
• Dutra RL, de Carvalho MB, Dos Santos M, et al. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx. PLoS One 2012;7(11):e50747
   Google Scholar
• Becker N, Nieters A, Chang-Claude J. The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12(6):582-3
   Google Scholar
• Jezequel P, Campion L, Joalland MP, et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004;90(1):189-93
   Google Scholar
• Spinola M, Leoni VP, Tanuma J, et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005;14(2):415-19
   Google Scholar
• Streit S, Mestel DS, Schmidt M, et al. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006;94(12):1879-86
   PubMedGoogle Scholar
• Vainikka S, Joukov V, Wennström S, et al. Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. J Biol Chem 1994;269(28):18320-6
   Google Scholar
• Freeman KW, Gangula RD, Welm BE, et al. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res 2003;63(19):6237-43
   Google Scholar
• Xian W, Schwertfeger KL, Rosen JM. Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelialmesenchymal transition. Mol Endocrinol 2007;21(4):987-1000
   Google Scholar
• Freeman KW, Welm BE, Gangula RD, et al. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res 2003;63(23):8256-63
   PubMed Web of Science ®Google Scholar
• Meijer D, Sieuwerts AM, Look MP, et al. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 2008;15(1):101-11
   Google Scholar
• Daniele G, Corral J, Molife LR, de Bono JS. FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep 2012;14:111-19
   PubMedGoogle Scholar
• Dimitroff CJ, Klohs W, Sharma A, et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999;17(2):121-35
   Google Scholar
• Ye T, Wei X, Yin T, et al. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res Treat 2014;143(3):435-46
   Google Scholar
• Sharpe R, Pearson A, Herrera-Abreu MT, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011;17(16):5275-86
   PubMed Web of Science ®Google Scholar
• Crose LE, Etheridge KT, Chen C, et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012;18(14):3780-90
   PubMed Web of Science ®Google Scholar
• Wang X, Kay A, Anak O, et al. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. J Clin Pharmacol 2013;53(1):14-20
   Google Scholar
• Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007;110(10):3729-34
   PubMed Web of Science ®Google Scholar
• Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001;98(13):3778-83
   PubMed Web of Science ®Google Scholar
• de Brito LR, Batey MA, Zhao Y, et al. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leuk Res 2011;35(9):1233-40
   Google Scholar
• Chen J, Deangelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101(40):14479-84
   PubMed Web of Science ®Google Scholar
• André F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013;19(13):3693-702
   PubMed Web of Science ®Google Scholar
• Issa A, Gill JW, Heideman MR, et al. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res 2013;15(1):R8
   PubMed Web of Science ®Google Scholar
• Dey JH, Bianchi F, Voshol J, et al. Targeting fibroblast growth factor receptors blocks PI3K/AKT signalling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010;15:4151-62
   Google Scholar
• Shiang CY, Qi Y, Wang B, et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat 2010;123(3):747-55
   PubMed Web of Science ®Google Scholar
• Rolfo C, Raez LE, Bronte G, et al. BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin Investig Drugs 2013;22(8):1081-8
   PubMed Web of Science ®Google Scholar
• Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011;54(20):7066-83
   PubMed Web of Science ®Google Scholar
• Guagnano V, Kauffmann A, Wöhrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012;2(12):1118-33
   PubMed Web of Science ®Google Scholar
• Chen TW, Bedard PL. Personalized medicine for metastatic breast cancer. Curr Opin Oncol 2013;25(6):615-24
   PubMed Web of Science ®Google Scholar
• Bello E, Colella G, Scarlato V, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011;71(4):1396-405
   PubMed Web of Science ®Google Scholar
• Bello E, Taraboletti G, Colella G, et al. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther 2013;12(2):131-40
   PubMed Web of Science ®Google Scholar
• Gozgit JM, Wong MJ, Moran L, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012;11(3):690-9
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369(19):1783-96
   PubMed Web of Science ®Google Scholar
• Bai A, Meetze K, Vo NY, et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 2010;70(19):7630-9
   PubMed Web of Science ®Google Scholar
• Zhao WM, Wang L, Park H, et al. Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res 2010;16(23):5750-8
   PubMed Web of Science ®Google Scholar
• Ceccarelli S, Romano F, Angeloni A, et al. Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages. Expert Opin Ther Targets 2012;16(4):377-93
   PubMed Web of Science ®Google Scholar
• Li S, Christensen C, Kiselyov VV, et al. Fibroblast growth factor-derived peptides: functional agonists of the fibroblast growth factor receptor. J Neurochem 2008;104(3):667-82
   Google Scholar
• Zhang H, Masuoka LB, Sadra AB, et al. 2007 LT FP-1039 (FGFR1:Fc), A soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. AACR-NCI-ERTC International Conference, San Francisco 2007. p. B55
   Google Scholar
• Harding TC, Long L, Palencia S, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013;5(178):178ra39
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9(1):28-39
   PubMed Web of Science ®Google Scholar
• Liang G, Liu Z, Wu J, et al. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012;33(10):531-41
   PubMed Web of Science ®Google Scholar
• Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 2010;70(13):5199-202
   Google Scholar
• Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013;19:3693-702
   PubMed Web of Science ®Google Scholar